Rheumatoid arthritis and the complement system

References

• Walport M. J. Complement. Second of two parts. N Engl J Med 2001; 344: 1140–4
   PubMed Web of Science ®Google Scholar
• Seelen M. A., Roos A., Daha M. R. Role of complement in innate and autoimmunity. J Nephrol 2005; 18: 642–53
   Google Scholar
• Kohl J. Drug evaluation: the C5a receptor antagonist PMX‐53. Curr Opin Mol Ther 2006; 8: 529–38
   PubMedGoogle Scholar
• Riedemann N. C., Guo R. F., Ward P. A. A key role of C5a/C5aR activation for the development of sepsis. J Leukoc Biol 2003; 74: 966–70
   PubMed Web of Science ®Google Scholar
• Law S., Reid K. Complement. IRL Press, OxfordUK 1988
   Google Scholar
• Kilgore K. S., Flory C. M., Miller B. F., Evans V. M., Warren J. S. The membrane attack complex of complement induces interleukin‐8 and monocyte chemoattractant protein‐1 secretion from human umbilical vein endothelial cells. Am J Pathol 1996; 149: 953–61
   PubMed Web of Science ®Google Scholar
• Reiter Y., Ciobotariu A., Fishelson Z. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Eur J Immunol 1992; 22: 1207–13
   PubMed Web of Science ®Google Scholar
• Fosbrink M., Niculescu F., Rus H. The role of c5b‐9 terminal complement complex in activation of the cell cycle and transcription. Immunol Res 2005; 31: 37–46
   PubMed Web of Science ®Google Scholar
• S Reis E., Falcao D. A., Isaac L. Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand J Immunol 2006; 63: 155–68
   Google Scholar
• Richards A., Kathryn Liszewski M., Kavanagh D., Fang C. J., Moulton E., Fremeaux‐Bacchi V., et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol 2007; 44: 111–22
   Google Scholar
• Zipfel P. F., Misselwitz J., Licht C., Skerka C. The role of defective complement control in hemolytic uremic syndrome. Semin Thromb Hemost 2006; 32: 146–54
   Google Scholar
• Zipfel P. F., Heinen S., Jozsi M., Skerka C. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol Immunol 2006; 43: 97–106
   PubMed Web of Science ®Google Scholar
• Schaumberg D. A., Hankinson S. E., Guo Q., Rimm E., Hunter D. J. A prospective study of 2 major age‐related macular degeneration susceptibility alleles and interactions with modifiable risk factors. Arch Ophthalmol 2007; 125: 55–62
   PubMed Web of Science ®Google Scholar
• Seelen M. A., Daha M. R. The role of complement in autoimmune renal disease. Autoimmunity 2006; 39: 411–5
   PubMed Web of Science ®Google Scholar
• Chan R. K., Ibrahim S. I., Takahashi K., Kwon E., McCormack M., Ezekowitz A., et al. The differing roles of the classical and mannose‐binding lectin complement pathways in the events following skeletal muscle ischemia‐reperfusion. J Immunol 2006; 177: 8080–5
   Google Scholar
• Biro E., Nieuwland R., Tak P. P., Pronk L. M., Schaap M. C., Sturk A., et al. Activated complement components and complement activator molecules on the surface of cell‐derived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann Rheum Dis 2007 Jan 29, (Epub ahead of print)
   Google Scholar
• Allegretti M., Moriconi A., Beccari A. R., Di Bitondo R., Bizzarri C., Bertini R., et al. Targeting C5a: recent advances in drug discovery. Curr Med Chem 2005; 12: 217–36
   PubMed Web of Science ®Google Scholar
• Rus H., Cudrici C., Niculescu F. C5b‐9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection. Ann Med 2005; 37: 97–104
   PubMed Web of Science ®Google Scholar
• Harpel P. C., Cooper N. R. Studies on human plasma C1 inactivator‐enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J Clin Invest 1975; 55: 593–604
   PubMed Web of Science ®Google Scholar
• Skidgel R. A., Kawahara M. S., Hugli T. E. Functional significance of the subunits of carboxypeptidase N (kininase I). Adv Exp Med Biol 1986; 198 Pt A: 375–80
   PubMedGoogle Scholar
• Kim D. D., Song W. C. Membrane complement regulatory proteins. Clin Immunol 2006; 118: 127–36
   PubMed Web of Science ®Google Scholar
• Tsiftsoglou S. A., Willis A. C., Li P., Chen X., Mitchell D. A., Rao Z., et al. The catalytically active serine protease domain of human complement factor I. Biochemistry 2005; 44: 6239–49
   Google Scholar
• Krushkal J., Bat O., Gigli I. Evolutionary relationships among proteins encoded by the regulator of complement activation gene cluster. Mol Biol Evol 2000; 17: 1718–30
   Google Scholar
• Carroll M. C., Alicot E. M., Katzman P. J., Klickstein L. B., Smith J. A., Fearon D. T. Organization of the genes encoding complement receptors type 1 and 2, decay‐accelerating factor, and C4‐binding protein in the RCA locus on human chromosome 1. J Exp Med 1988; 167: 1271–80
   PubMed Web of Science ®Google Scholar
• Blom A. M., Kask L., Ramesh B., Hillarp A. Effects of zinc on factor I cofactor activity of C4b‐binding protein and factor H. Arch Biochem Biophys 2003; 418: 108–18
   PubMed Web of Science ®Google Scholar
• Schwaeble W., Zwirner J., Schulz T. F., Linke R. P., Dierich M. P., Weiss E. H. Human complement factor H: expression of an additional truncated gene product of 43 kDa in human liver. Eur J Immunol 1987; 17: 1485–9
   PubMed Web of Science ®Google Scholar
• McRae J. L., Murphy B. E., Eyre H. J., Sutherland G. R., Crawford J., Cowan P. J. Location and structure of the human FHR‐5 gene. Genetica 2002; 114: 157–61
   Google Scholar
• Fu J., Lin G., Zeng B., Wu Z., Wu Y., Chu H., et al. Anti‐ischemia/reperfusion of C1 inhibitor in myocardial cell injury via regulation of local myocardial C3 activity. Biochem Biophys Res Commun 2006; 350: 162–8
   PubMed Web of Science ®Google Scholar
• Mulligan M. S., Warner R. L., Rittershaus C. W., Thomas L. J., Ryan U. S., Foreman K. E., et al. Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties. J Immunol 1999; 162: 4952–9
   PubMed Web of Science ®Google Scholar
• Hillmen P., Young N. S., Schubert J., Brodsky R. A., Socie G., Muus P., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233–43
   PubMed Web of Science ®Google Scholar
• Kirschfink M. C1‐inhibitor and transplantation. Immunobiology 2002; 205: 534–41
   Google Scholar
• Smith C. A., Arnett F. C. Epidemiologic aspects of rheumatoid arthritis. Current immunogenetic approach. Clin Orthop Relat Res 1991; 1991: 23–35
   Google Scholar
• Feldmann M., Brennan F. M., Maini R. N. Rheumatoid arthritis. Cell 1996; 85: 307–10
   PubMed Web of Science ®Google Scholar
• Lark M. W., Bayne E. K., Flanagan J., Harper C. F., Hoerrner L. A., Hutchinson N. I., et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 1997; 100: 93–106
   PubMed Web of Science ®Google Scholar
• Szekanecz Z., Gaspar L., Koch A. E. Angiogenesis in rheumatoid arthritis. Front Biosci 2005; 10: 1739–53
   PubMedGoogle Scholar
• Schett G. Rheumatoid arthritis: inflammation and bone loss. Wien Med Wochenschr 2006; 156: 34–41
   PubMedGoogle Scholar
• Gregersen P. K., Silver J., Winchester R. J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205–13
   PubMed Web of Science ®Google Scholar
• Plenge R. M., Padyukov L., Remmers E. F., Purcell S., Lee A. T., Karlson E. W., et al. Replication of putative candidate‐gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005; 77: 1044–60
   PubMed Web of Science ®Google Scholar
• Wandstrat A., Wakeland E. The genetics of complex autoimmune diseases: non‐MHC susceptibility genes. Nat Immunol 2001; 2: 802–9
   PubMedGoogle Scholar
• Klareskog L., Padyukov L., Ronnelid J., Alfredsson L. Genes, environment and immunity in the development of rheumatoid arthritis. Curr Opin Immunol 2006; 18: 650–5
   PubMed Web of Science ®Google Scholar
• Weissmann G. Pathogenesis of rheumatoid arthritis. J Clin Rheumatol 2004; 10: S26–31
   Google Scholar
• Aho K., Palosuo T., Raunio V., Puska P., Aromaa A., Salonen J. T. When does rheumatoid disease start?. Arthritis Rheum 1985; 28: 485–9
   PubMed Web of Science ®Google Scholar
• Rantapaa‐Dahlqvist S., de Jong B. A., Berglin E., Hallmans G., Wadell G., Stenlund H., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2741–9
   PubMed Web of Science ®Google Scholar
• Mewar D., Wilson A. G. Autoantibodies in rheumatoid arthritis: a review. Biomed Pharmacother 2006; 60: 648–55
   PubMed Web of Science ®Google Scholar
• Hepburn A. L., Mason J. C., Wang S., Shepherd C. J., Florey O., Haskard D. O., et al. Both Fcgamma and complement receptors mediate transfer of immune complexes from erythrocytes to human macrophages under physiological flow conditions in vitro. Clin Exp Immunol 2006; 146: 133–45
   PubMed Web of Science ®Google Scholar
• Morgan B. P., Daniels R. H., Williams B. D. Measurement of terminal complement complexes in rheumatoid arthritis. Clin Exp Immunol 1988; 73: 473–8
   Google Scholar
• Swaak A. J., Van Rooyen A., Planten O., Han H., Hattink O., Hack E. An analysis of the levels of complement components in the synovial fluid in rheumatic diseases. Clin Rheumatol 1987; 6: 350–7
   PubMed Web of Science ®Google Scholar
• Brodeur J. P., Ruddy S., Schwartz L. B., Moxley G. Synovial fluid levels of complement SC5b‐9 and fragment Bb are elevated in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1531–7
   Google Scholar
• Corvetta A., Pomponio G., Rinaldi N., Luchetti M. M., Di Loreto C., Stramazzotti D. Terminal complement complex in synovial tissue from patients affected by rheumatoid arthritis, osteoarthritis and acute joint trauma. Clin Exp Rheumatol 1992; 10: 433–8
   PubMed Web of Science ®Google Scholar
• Hogasen K., Mollnes T. E., Harboe M., Gotze O., Hammer H. B., Oppermann M. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid. J Rheumatol 1995; 22: 24–8
   Google Scholar
• Moxley G., Ruddy S. Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis. Arthritis Rheum 1985; 28: 1089–95
   PubMed Web of Science ®Google Scholar
• Jose P. J., Moss I. K., Maini R. N., Williams T. J. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. Ann Rheum Dis 1990; 49: 747–52
   PubMed Web of Science ®Google Scholar
• Woolley D. E., Tetlow L. C. Observations on the microenvironmental nature of cartilage degradation in rheumatoid arthritis. Ann Rheum Dis 1997; 56: 151–61
   Web of Science ®Google Scholar
• Tetlow L. C., Harper N., Dunningham T., Morris M. A., Bertfield H., Woolley D. E. Effects of induced mast cell activation on prostaglandin E and metalloproteinase production by rheumatoid synovial tissue in vitro. Ann Rheum Dis 1998; 57: 25–32
   Google Scholar
• Jahn B., Von Kempis J., Kramer K. L., Filsinger S., Hansch G. M. Interaction of the terminal complement components C5b‐9 with synovial fibroblasts: binding to the membrane surface leads to increased levels in collagenase‐specific mRNA. Immunology 1993; 78: 329–34
   Google Scholar
• Crockard A. D., Thompson J. M., McBride S. J., Edgar J. D., McNeill T. A., Bell A. L. Markers of inflammatory activation: upregulation of complement receptors CR1 and CR3 on synovial fluid neutrophils from patients with inflammatory joint disease. Clin Immunol Immunopathol 1992; 65: 135–42
   PubMedGoogle Scholar
• Yuan G., Wei J., Zhou J., Hu H., Tang Z., Zhang G. Expression of C5aR (CD88) of synoviocytes isolated from patients with rheumatoid arthritis and osteoarthritis. Chin Med J (Engl) 2003; 116: 1408–12
   PubMed Web of Science ®Google Scholar
• Wouters D., Voskuyl A. E., Molenaar E. T., Dijkmans B. A., Hack C. E. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q‐C4 complexes as novel activation products. Arthritis Rheum 2006; 54: 1143–50
   PubMedGoogle Scholar
• Berckmans R. J., Nieuwland R., Tak P. P., Boing A. N., Romijn F. P., Kraan M. C., et al. Cell‐derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII‐dependent mechanism. Arthritis Rheum 2002; 46: 2857–66
   PubMed Web of Science ®Google Scholar
• Makinde V. A., Senaldi G., Jawad A. S., Berry H., Vergani D. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway. Ann Rheum Dis 1989; 48: 302–6
   PubMed Web of Science ®Google Scholar
• Aggarwal A., Bhardwaj A., Alam S., Misra R. Evidence for activation of the alternate complement pathway in patients with juvenile rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 189–92
   PubMed Web of Science ®Google Scholar
• Jarvis J. N., Taylor H., Iobidze M., Krenz M. Complement activation and immune complexes in children with polyarticular juvenile rheumatoid arthritis: a longitudinal study. J Rheumatol 1994; 21: 1124–7
   Google Scholar
• Schaapherder A. F., Gooszen H. G., te Bulte M. T., Daha M. R. Human complement activation via the alternative pathway on porcine endothelium initiated by IgA antibodies. Transplantation 1995; 60: 287–91
   Google Scholar
• Jarvis J. N., Iobidze M., Taylor H., DeJonge J., Chang S. A comparison of immunoglobulin G‐containing high‐molecular‐weight complexes isolated from children with juvenile rheumatoid arthritis and congenital human immunodeficiency virus infection. Pediatr Res 1993; 34: 781–4
   Google Scholar
• van Zeben D., Hazes J. M., Zwinderman A. H., Cats A., van der Voort E. A., Breedveld F. C. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992; 51: 1029–35
   PubMed Web of Science ®Google Scholar
• Hanauske‐Abel H. M., Pontz B. F., Schorlemmer H. U. Cartilage specific collagen activates macrophages and the alternative pathway of complement: evidence for an immunopathogenic concept of rheumatoid arthritis. Ann Rheum Dis 1982; 41: 168–76
   Google Scholar
• Arnold J. N., Dwek R. A., Rudd P. M., Sim R. B. Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol Lett 2006; 106: 103–10
   PubMed Web of Science ®Google Scholar
• Sato R., Matsushita M., Miyata M., Sato Y., Kasukawa R., Fujita T. Substances reactive with mannose‐binding protein (MBP) in sera of patients with rheumatoid arthritis. Fukushima J Med Sci 1997; 43: 99–111
   PubMedGoogle Scholar
• Kilpatrick D. C. Mannan‐binding lectin and its role in innate immunity. Transfus Med 2002; 12: 335–52
   PubMed Web of Science ®Google Scholar
• Arend W. P. The innate immune system in rheumatoid arthritis. Arthritis Rheum 2001; 44: 2224–34
   PubMed Web of Science ®Google Scholar
• Nauta A. J., Raaschou‐Jensen N., Roos A., Daha M. R., Madsen H. O., Borrias‐Essers M. C., et al. Mannose‐binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol 2003; 33: 2853–63
   PubMedGoogle Scholar
• Kemp P. A., Spragg J. H., Brown J. C., Morgan B. P., Gunn C. A., Taylor P. W. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen‐specific monoclonal antibodies. J Clin Lab Immunol 1992; 37: 147–62
   Google Scholar
• Morgan K., Clague R. B., Shaw M. J., Firth S. A., Twose T. M., Holt P. J. Native type II collagen‐induced arthritis in the rat: the effect of complement depletion by cobra venom factor. Arthritis Rheum 1981; 24: 1356–62
   PubMed Web of Science ®Google Scholar
• Joe B., Wilder R. L. Animal models of rheumatoid arthritis. Mol Med Today 1999; 5: 367–9
   PubMedGoogle Scholar
• Lindqvist A. K., Johannesson M., Johansson A. C., Nandakumar K. S., Blom A. M., Holmdahl R. Backcross and partial advanced intercross analysis of nonobese diabetic gene‐mediated effects on collagen‐induced arthritis reveals an interactive effect by two major loci. J Immunol 2006; 177: 3952–9
   Google Scholar
• Spinella D. G., Jeffers J. R., Reife R. A., Stuart J. M. The role of C5 and T‐cell receptor Vb genes in susceptibility to collagen‐induced arthritis. Immunogenetics 1991; 34: 23–7
   PubMedGoogle Scholar
• Ji H., Gauguier D., Ohmura K., Gonzalez A., Duchatelle V., Danoy P., et al. Genetic influences on the end‐stage effector phase of arthritis. J Exp Med 2001; 194: 321–30
   Google Scholar
• McIndoe R. A., Bohlman B., Chi E., Schuster E., Lindhardt M., Hood L. Localization of non‐Mhc collagen‐induced arthritis susceptibility loci in DBA/1j mice. Proc Natl Acad Sci U S A 1999; 96: 2210–4
   PubMed Web of Science ®Google Scholar
• Baxter A. G., Cooke A. Complement lytic activity has no role in the pathogenesis of autoimmune diabetes in NOD mice. Diabetes 1993; 42: 1574–8
   PubMed Web of Science ®Google Scholar
• Wetsel R. A., Fleischer D. T., Haviland D. L. Deficiency of the murine fifth complement component (C5). A 2‐base pair gene deletion in a 5'‐exon. J Biol Chem 1990; 265: 2435–40
   PubMed Web of Science ®Google Scholar
• Wang Y., Kristan J., Hao L., Lenkoski C. S., Shen Y., Matis L. A. A role for complement in antibody‐mediated inflammation: C5‐deficient DBA/1 mice are resistant to collagen‐induced arthritis. J Immunol 2000; 164: 4340–7
   PubMed Web of Science ®Google Scholar
• Hietala M. A., Jonsson I. M., Tarkowski A., Kleinau S., Pekna M. Complement deficiency ameliorates collagen‐induced arthritis in mice. J Immunol 2002; 169: 454–9
   PubMedGoogle Scholar
• Banda N. K., Thurman J. M., Kraus D., Wood A., Carroll M. C., Arend W. P., et al. Alternative complement pathway activation is essential for inflammation and joint destruction in the passive transfer model of collagen‐induced arthritis. J Immunol 2006; 177: 1904–12
   PubMedGoogle Scholar
• Hietala M. A., Nandakumar K. S., Persson L., Fahlen S., Holmdahl R., Pekna M. Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis. Eur J Immunol 2004; 34: 1208–16
   PubMed Web of Science ®Google Scholar
• Nandakumar K. S., Holmdahl R. Antibody‐induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res Ther 2007; 8: 223
   Google Scholar
• Wang Y., Rollins S. A., Madri J. A., Matis L. A. Anti‐C5 monoclonal antibody therapy prevents collagen‐induced arthritis and ameliorates established disease. Proc Natl Acad Sci U S A 1995; 92: 8955–9
   PubMed Web of Science ®Google Scholar
• Ji H., Ohmura K., Mahmood U., Lee D. M., Hofhuis F. M., Boackle S. A., et al. Arthritis critically dependent on innate immune system players. Immunity 2002; 16: 157–68
   PubMed Web of Science ®Google Scholar
• Matsumoto I., Staub A., Benoist C., Mathis D. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999; 286: 1732–5
   PubMed Web of Science ®Google Scholar
• Sjoberg A., Onnerfjord P., Morgelin M., Heinegard D., Blom A. M. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J Biol Chem 2005; 280: 32301–8
   PubMed Web of Science ®Google Scholar
• Bengtsson E., Neame P. J., Heinegard D., Sommarin Y. The primary structure of a basic leucine‐rich repeat protein, PRELP, found in connective tissues. J Biol Chem 1995; 270: 25639–44
   PubMed Web of Science ®Google Scholar
• Groeneveld T. W., Oroszlan M., Owens R. T., Faber‐Krol M. C., Bakker A. C., Arlaud G. J., et al. Interactions of the extracellular matrix proteoglycans decorin and biglycan with C1q and collectins. J Immunol 2005; 175: 4715–23
   PubMed Web of Science ®Google Scholar
• Barilla M. L., Carsons S. E. Fibronectin fragments and their role in inflammatory arthritis. Semin Arthritis Rheum 2000; 29: 252–65
   PubMed Web of Science ®Google Scholar
• Bohnsack J. F., Tenner A. J., Laurie G. W., Kleinman H. K., Martin G. R., Brown E. J. The C1q subunit of the first component of complement binds to laminin: a mechanism for the deposition and retention of immune complexes in basement membrane. Proc Natl Acad Sci U S A 1985; 82: 3824–8
   Google Scholar
• Oldberg A., Antonsson P., Lindblom K., Heinegard D. A collagen‐binding 59‐kd protein (fibromodulin) is structurally related to the small interstitial proteoglycans PG‐S1 and PG‐S2 (decorin). EMBO J 1989; 8: 2601–4
   PubMed Web of Science ®Google Scholar
• Benjamin M., Ralphs J. R. Biology of fibrocartilage cells. Int Rev Cytol 2004; 233: 1–45
   PubMed Web of Science ®Google Scholar
• Svensson L., Aszodi A., Reinholt F. P., Fassler R., Heinegard D., Oldberg A. Fibromodulin‐null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon. J Biol Chem 1999; 274: 9636–47
   PubMed Web of Science ®Google Scholar
• Heathfield T. F., Onnerfjord P., Dahlberg L., Heinegard D. Cleavage of fibromodulin in cartilage explants involves removal of the N‐terminal tyrosine sulfate‐rich region by proteolysis at a site that is sensitive to matrix metalloproteinase‐13. J Biol Chem 2004; 279: 6286–95
   PubMed Web of Science ®Google Scholar
• Krumdieck R., Hook M., Rosenberg L. C., Volanakis J. E. The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex. J Immunol 1992; 149: 3695–701
   PubMed Web of Science ®Google Scholar
• Poole A. R., Webber C., Pidoux I., Choi H., Rosenberg L. C. Localization of a dermatan sulfate proteoglycan (DS‐PGII) in cartilage and the presence of an immunologically related species in other tissues. J Histochem Cytochem 1986; 34: 619–25
   PubMed Web of Science ®Google Scholar
• Kim H. J., Berek C. B cells in rheumatoid arthritis. Arthritis Res 2000; 2: 126–31
   PubMedGoogle Scholar
• Schroder A. E., Greiner A., Seyfert C., Berek C. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci U S A 1996; 93: 221–5
   PubMed Web of Science ®Google Scholar
• Roosnek E., Lanzavecchia A. Efficient and selective presentation of antigen‐antibody complexes by rheumatoid factor B cells. J Exp Med 1991; 173: 487–9
   PubMed Web of Science ®Google Scholar
• Chan O. T., Hannum L. G., Haberman A. M., Madaio M. P., Shlomchik M. J. A novel mouse with B cells but lacking serum antibody reveals an antibody‐independent role for B cells in murine lupus. J Exp Med 1999; 189: 1639–48
   PubMed Web of Science ®Google Scholar
• Lindhout E., van Eijk M., van Pel M., Lindeman J., Dinant H. J., de Groot C. Fibroblast‐like synoviocytes from rheumatoid arthritis patients have intrinsic properties of follicular dendritic cells. J Immunol 1999; 162: 5949–56
   Google Scholar
• Clark E. A., Ledbetter J. A. How does B cell depletion therapy work, and how can it be improved?. Ann Rheum Dis 2005; 64(Suppl 4)77–80
   Google Scholar
• Shan D., Ledbetter J. A., Press O. W. Signaling events involved in anti‐CD20‐induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48: 673–83
   PubMed Web of Science ®Google Scholar
• Edwards J. C., Szczepanski L., Szechinski J., Filipowicz‐Sosnowska A., Emery P., Close D. R., et al. Efficacy of B‐cell‐targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572–81
   PubMed Web of Science ®Google Scholar
• Chan H. T., Hughes D., French R. R., Tutt A. L., Walshe C. A., Teeling J. L., et al. CD20‐induced lymphoma cell death is independent of both caspases and its redistribution into triton X‐100 insoluble membrane rafts. Cancer Res 2003; 63: 5480–9
   PubMed Web of Science ®Google Scholar
• Di Gaetano N., Cittera E., Nota R., Vecchi A., Grieco V., Scanziani E., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581–7
   PubMed Web of Science ®Google Scholar
• Bannerji R., Kitada S., Flinn I. W., Pearson M., Young D., Reed J. C., et al. Apoptotic‐regulatory and complement‐protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003; 21: 1466–71
   PubMed Web of Science ®Google Scholar
• van der Kolk L. E., Grillo‐Lopez A. J., Baars J. W., Hack C. E., van Oers M. H. Complement activation plays a key role in the side‐effects of rituximab treatment. Br J Haematol 2001; 115: 807–11
   PubMed Web of Science ®Google Scholar
• Giles J. T., Bathon J. M. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004; 19: 320–34
   PubMedGoogle Scholar
• Breedveld F. New tumor necrosis factor‐alpha biologic therapies for rheumatoid arthritis. Eur Cytokine Netw 1998; 9: 233–8
   Google Scholar
• Strangfeld A., Listing J. Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti‐TNF therapy. Best Pract Res Clin Rheumatol 2006; 20: 1181–95
   PubMed Web of Science ®Google Scholar
• Desai S. B., Furst D. E. Problems encountered during anti‐tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20: 757–90
   PubMed Web of Science ®Google Scholar
• Quigg R. J. Use of complement inhibitors in tissue injury. Trends Mol Med 2002; 8: 430–6
   PubMed Web of Science ®Google Scholar
• Krych‐Goldberg M., Atkinson J. P. Structure‐function relationships of complement receptor type 1. Immunol Rev 2001; 180: 112–22
   PubMed Web of Science ®Google Scholar
• Yoon S. H., Fearon D. T. Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma. J Immunol 1985; 134: 3332–8
   PubMed Web of Science ®Google Scholar
• Linton S. M., Williams A. S., Dodd I., Smith R., Williams B. D., Morgan B. P. Therapeutic efficacy of a novel membrane‐targeted complement regulator in antigen‐induced arthritis in the rat. Arthritis Rheum 2000; 43: 2590–7
   PubMedGoogle Scholar
• Rioux P. TP‐10 (AVANT Immunotherapeutics). Curr Opin Investig Drugs 2001; 2: 364–71
   PubMedGoogle Scholar
• Zimmerman J. L., Dellinger R. P., Straube R. C., Levin J. L. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med 2000; 28: 3149–54
   PubMed Web of Science ®Google Scholar
• Schmid R. A., Hillinger S., Hamacher J., Stammberger U. TP20 is superior to TP10 in reducing ischemia/reperfusion injury in rat lung grafts. Transplant Proc 2001; 33: 948–9
   PubMed Web of Science ®Google Scholar
• Thomas T. C., Rollins S. A., Rother R. P., Giannoni M. A., Hartman S. L., Elliott E. A., et al. Inhibition of complement activity by humanized anti‐C5 antibody and single‐chain Fv. Mol Immunol 1996; 33: 1389–401
   PubMed Web of Science ®Google Scholar
• Tesser J., Kivitz A., Fleischmann R., Mojcik C. F., Bombara M., Phoneix F. B. Safety and efficacy of the humanized anti‐C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum 2001; S214
   Google Scholar
• Burch F., Tesser J., Bell L., Kivitz A. Baseline C5b‐9 level correlates with CRP and ACR 20 response to the humanized anti‐C5 antibody hG51.1 in patients with rheumatoid arthritis. Arthritis Rheum 2001; S274
   Google Scholar
• Mizuno M. A review of current knowledge of the complement system and the therapeutic opportunities in inflammatory arthritis. Curr Med Chem 2006; 13: 1707–17
   Google Scholar
• Johansson A. C., Sundler M., Kjellen P., Johannesson M., Cook A., Lindqvist A. K., et al. Genetic control of collagen‐induced arthritis in a cross with NOD and C57BL/10 mice is dependent on gene regions encoding complement factor 5 and FcgammaRIIb and is not associated with loci controlling diabetes. Eur J Immunol 2001; 31: 1847–56
   Google Scholar
• Solomon S., Kolb C., Mohanty S., Jeisy‐Walder E., Preyer R., Schollhorn V., et al. Transmission of antibody‐induced arthritis is independent of complement component 4 (C4) and the complement receptors 1 and 2 (CD21/35). Eur J Immunol 2002; 32: 644–51
   Google Scholar
• Dreja H., Annenkov A., Chernajovsky Y. Soluble complement receptor 1 (CD35) delivered by retrovirally infected syngeneic cells or by naked DNA injection prevents the progression of collagen‐induced arthritis. Arthritis Rheum 2000; 43: 1698–709
   PubMed Web of Science ®Google Scholar
• Koga T., Kakimoto K., Hirofuji T., Kotani S., Ohkuni H., Watanabe K., et al. Acute joint inflammation in mice after systemic injection of the cell wall, its peptidoglycan, and chemically defined peptidoglycan subunits from various bacteria. Infect Immun 1985; 50: 27–34
   PubMed Web of Science ®Google Scholar
• van Lent P. L., van den Bersselaar L. A., van den Hoek A. E., van de Loo A. A., van den Berg W. B. Cationic immune complex arthritis in mice—a new model. Synergistic effect of complement and interleukin‐1. Am J Pathol 1992; 140: 1451–61
   PubMed Web of Science ®Google Scholar
• Mizuno M., Nishikawa K., Morgan B. P., Matsuo S. Comparison of the suppressive effects of soluble CR1 and C5a receptor antagonist in acute arthritis induced in rats by blocking of CD59. Clin Exp Immunol 2000; 119: 368–75
   PubMed Web of Science ®Google Scholar
• Goodfellow R. M., Williams A. S., Levin J. L., Williams B. D., Morgan B. P. Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen‐induced arthritis. Clin Exp Immunol 2000; 119: 210–6
   PubMed Web of Science ®Google Scholar
• Goodfellow R. M., Williams A. S., Levin J. L., Williams B. D., Morgan B. P. Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono‐articular arthritis. Clin Exp Immunol 1997; 110: 45–52
   PubMed Web of Science ®Google Scholar
• Ino Y., Sato T., Koshiyama Y., Suzuki K., Oda M., Iwaki M. Effects of FUT‐175, a novel synthetic protease inhibitor, on the development of adjuvant arthritis in rats and some biological reactions dependent on complement activation. Gen Pharmacol 1987; 18: 513–6
   Google Scholar
• Ames R. S., Lee D., Foley J. J., Jurewicz A. J., Tornetta M. A., Bautsch W., et al. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol 2001; 166: 6341–8
   PubMed Web of Science ®Google Scholar
• Woodruff T. M., Strachan A. J., Dryburgh N., Shiels I. A., Reid R. C., Fairlie D. P., et al. Antiarthritic activity of an orally active C5a receptor antagonist against antigen‐induced monarticular arthritis in the rat. Arthritis Rheum 2002; 46: 2476–85
   PubMed Web of Science ®Google Scholar
• Harris C. L., Williams A. S., Linton S. M., Morgan B. P. Coupling complement regulators to immunoglobulin domains generates effective anti‐complement reagents with extended half‐life in vivo. Clin Exp Immunol 2002; 129: 198–207
   PubMed Web of Science ®Google Scholar
• Fraser D. A., Harris C. L., Williams A. S., Mizuno M., Gallagher S., Smith R. A., et al. Generation of a recombinant, membrane‐targeted form of the complement regulator CD59: activity in vitro and in vivo. J Biol Chem 2003; 278: 48921–7
   Google Scholar